| [ Summary ] |
The intimal hyperplasia in vascular access (VA) is always hydrodynamically generated because of the anatomical character of veins. The pharmacotherapy for VA stenosis has been reported on from the viewpoint of preventing shear stress,reducing endothelial disorders, inhibition of monocytes, macrophage migration, smooth muscle cellproliferation, extramatrix production, and genetherapy. However, few definitive findings exist atthis time. Furthermore, it has been reported that antihypertensive agents and antiplatelet agentshave been shown to reduce intimal hyperplasia andvascular inflammation. However, the results from USRDS and DOPPS data do not provide consistentopinions. Therefore, randomized prospective multicenter studies on pharmacotherapy for the prevention of VA stenosis in our country, where over 90% patients use AVF for VA, will be necessary in the future. |